Selective protein separation based mostly on cost anisotropy by spherical polyelectrolyte brushes
Protein purification is of significant significance within the meals business, drug discovery and different associated fields. Amongst many separation strategies, polyelectrolyte (PE)-based section separation is developed and acknowledged as a low-cost purification approach. On this work, spherical polyelectrolyte brushes (SPBs) with excessive particular floor space was utilized to review the protein accessibility and selective protein binding on extremely charged nanoparticles (NPs) in addition to the selective section separation of proteins.
The correlation between cost anisotropy, protein binding, and section separation was investigated on numerous protein programs together with these proteins with comparable isoelectric factors (pI) similar to bovine serum albumin (BSA) and β-lactoglobulin (BLG), proteins with comparable molecular weights similar to BSA and hemoglobin (HB), and even protein variants (BLG-A and -B) with tiny distinction of amino acids.
The non-specific electrostatic interplay studied by turbidimetric titrations and isothermal calorimetry titration (ITC) signifies a particular binding between proteins and SPBs arising from the cost anisotropy of proteins.
An optimized output based mostly on selective protein binding on SPBs may very well be correlated for environment friendly protein separation by tuning exterior situations together with pH and ionic power. These findings due to this fact proved that section separation based mostly on selective protein adsorption by SPBs was an environment friendly various for proteins separation in contrast with conventional follow.
Reengineering anthrax toxin protecting antigen for improved receptor-specific protein supply
Background: To extend the scale of the druggable proteome, it will be extremely fascinating to plan environment friendly strategies to translocate designed binding proteins to the cytosol, as they might particularly goal flat and hydrophobic protein-protein interfaces.
If this may very well be carried out in a fashion depending on a cell floor receptor, two layers of specificity could be obtained: one for the cell sort and the opposite for the cytosolic goal. Bacterial protein toxins have naturally developed such programs.
Anthrax toxin consists of a pore-forming translocation unit (protecting antigen (PA)) and a separate protein payload. When engineering PA to ablate binding to its personal receptor and as an alternative binding to a receptor of alternative, by fusing a designed ankyrin repeat protein (DARPin), uptake in new cell varieties will be achieved.
Outcomes: Prepore-to-pore conversion of redirected PA already happens on the cell floor, limiting the quantity of PA that may be administered and thus limiting the quantity of delivered payload. We hypothesized that the reason being a scarcity of a stabilizing interplay with wild-type PA receptor.
We’ve got now reengineered PA to include the binding area of the anthrax receptor CMG2, adopted by a DARPin, binding to the receptor of alternative. This assemble is certainly stabilized, undergoes prepore-to-pore conversion solely in late endosomes, will be administered to a lot greater concentrations with out displaying toxicity, and consequently delivers a lot greater quantities of payload to the cytosol.
Conclusion: We imagine that this reengineered system is a vital step ahead to addressing environment friendly cell-specific supply of proteins to the cytosol.
Key phrases: Anthrax toxin; Cytosolic protein supply; DARPin; Protecting antigen.
Amylin (Peptide) (PE) |
|||
MBS6462865-5x01mL | MyBiosource | 5x0.1mL | EUR 2840 |
Amylin (Peptide) (APC) |
|||
MBS6462856-01mL | MyBiosource | 0.1mL | EUR 665 |
Amylin (Peptide) (APC) |
|||
MBS6462856-5x01mL | MyBiosource | 5x0.1mL | EUR 2840 |
Amylin (Peptide) (HRP) |
|||
MBS6462859-01mL | MyBiosource | 0.1mL | EUR 665 |
Amylin (Peptide) (HRP) |
|||
MBS6462859-5x01mL | MyBiosource | 5x0.1mL | EUR 2840 |
Amylin (Peptide) (FITC) |
|||
MBS6462858-01mL | MyBiosource | 0.1mL | EUR 665 |
Amylin (Peptide) (FITC) |
|||
MBS6462858-5x01mL | MyBiosource | 5x0.1mL | EUR 2840 |
Amylin (Peptide) (Biotin) |
|||
MBS6462857-01mL | MyBiosource | 0.1mL | EUR 665 |
Amylin (Peptide) (Biotin) |
|||
MBS6462857-5x01mL | MyBiosource | 5x0.1mL | EUR 2840 |
Amylin Peptide, Antibody |
|||
GWB-169F69 | GenWay Biotech | 1 ml | Ask for price |
Amylin Peptide, Antibody |
|||
GWB-86CDD1 | GenWay Biotech | 1 ml | Ask for price |
Amylin Peptide, Antibody |
|||
GWB-DE14E9 | GenWay Biotech | 7 ml | Ask for price |
Amylin (20-29) Peptide |
|||
20-abx265112 | Abbexa |
|
|
Amylin (Feline) |
|||
017-01 | PHOENIX PEPTIDE | 500 μg | EUR 355.32 |
Anantin (linear sequence) Peptide |
|||
abx266971-1ml | Abbexa | 1 ml | EUR 762.5 |
Anantin (linear sequence) Peptide |
|||
abx266971-200l | Abbexa | 200 µl | EUR 325 |
Amylin (IAPP) Peptide |
|||
20-abx266530 | Abbexa |
|
|
Amylin (14-24) (Human) |
|||
017-08 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
Amylin (20-29) (Human) |
|||
017-09 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
Amylin (17-37) (Human) |
|||
017-15 | PHOENIX PEPTIDE | 100 μg | EUR 140.4 |
Amylin (24-37) (Human) |
|||
017-16 | PHOENIX PEPTIDE | 100 μg | EUR 140.4 |
Amylin (Peptide) (MaxLight 405) |
|||
MBS6462860-01mL | MyBiosource | 0.1mL | EUR 665 |
Amylin (Peptide) (MaxLight 405) |
|||
MBS6462860-5x01mL | MyBiosource | 5x0.1mL | EUR 2840 |
Amylin (Peptide) (MaxLight 490) |
|||
MBS6462861-01mL | MyBiosource | 0.1mL | EUR 665 |
Amylin (Peptide) (MaxLight 490) |
|||
MBS6462861-5x01mL | MyBiosource | 5x0.1mL | EUR 2840 |
Amylin (Peptide) (MaxLight 550) |
|||
MBS6462862-01mL | MyBiosource | 0.1mL | EUR 665 |
Amylin (Peptide) (MaxLight 550) |
|||
MBS6462862-5x01mL | MyBiosource | 5x0.1mL | EUR 2840 |
Amylin (Peptide) (MaxLight 650) |
|||
MBS6462863-01mL | MyBiosource | 0.1mL | EUR 665 |
Amylin (Peptide) (MaxLight 650) |
|||
MBS6462863-5x01mL | MyBiosource | 5x0.1mL | EUR 2840 |
Amylin (20-29) (Feline) |
|||
017-02 | PHOENIX PEPTIDE | 200 μg | EUR 73.44 |
Amylin (8-37) (Rat) |
|||
017-14 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
LL 37, reverse sequence Peptide |
|||
abx267003-1ml | Abbexa | 1 ml | EUR 975 |
LL 37, reverse sequence Peptide |
|||
abx267003-200l | Abbexa | 200 µl | EUR 400 |
Amylin (1-13) (Human) |
|||
017-06 | PHOENIX PEPTIDE | 200 μg | EUR 108 |
Amylin Blocking Peptide |
|||
20-abx062762 | Abbexa |
|
|
Amylin Blocking Peptide |
|||
DF7715-BP | Affbiotech | 1mg | EUR 234 |
Amylin Blocking Peptide |
|||
MBS823767-1mg | MyBiosource | 1mg | EUR 190 |
Amylin Blocking Peptide |
|||
MBS823767-5mg | MyBiosource | 5mg | EUR 345 |
Amylin Blocking Peptide |
|||
MBS823767-5x5mg | MyBiosource | 5x5mg | EUR 1465 |
Amylin Blocking Peptide |
|||
MBS9627007-1mg | MyBiosource | 1mg | EUR 380 |
Amylin Blocking Peptide |
|||
MBS9627007-5x1mg | MyBiosource | 5x1mg | EUR 1650 |
Amylin (Rat, Mouse) |
|||
017-11 | PHOENIX PEPTIDE | 500 μg | EUR 355.32 |
Amylin / IAPP (Human) |
|||
017-03 | PHOENIX PEPTIDE | 100 μg | EUR 140.4 |
Amylin amide (Human) |
|||
017-04 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
Amylin (25-37) amide (Human) |
|||
017-10 | PHOENIX PEPTIDE | 500 μg | EUR 86.4 |
Erythropoietin Mimetic Peptide Sequence 20 |
|||
H-4344.0001 | Bachem | 1.0mg | EUR 544.8 |
Description: Sum Formula: C72H99N17O17S2; CAS# [203397-62-0] net |
Erythropoietin Mimetic Peptide Sequence 20 |
|||
H-4344.0005 | Bachem | 5.0mg | EUR 2067.6 |
Description: Sum Formula: C72H99N17O17S2; CAS# [203397-62-0] net |
[Tyr0]-Amylin (1-13) (Human) |
|||
017-07 | PHOENIX PEPTIDE | 100 μg | EUR 355.32 |
Amylin (Feline) - Antibody |
|||
H-017-01 | PHOENIX PEPTIDE | 50 μl | EUR 238.68 |
Substance P reversed sequence Peptide |
|||
20-abx266314 | Abbexa |
|
|
Substance P reversed sequence Peptide |
|||
abx266314-100l | Abbexa | 100 µl | EUR 312.5 |
Substance P reversed sequence Peptide |
|||
abx266314-1ml | Abbexa | 1 ml | EUR 812.5 |
Substance P reversed sequence Peptide |
|||
abx266314-200l | Abbexa | 200 µl | EUR 462.5 |
Amylin (1-13) (Human) - Antibody |
|||
H-017-06 | PHOENIX PEPTIDE | 100 μl | EUR 295.92 |
Amylin (Feline) - RIA Kit |
|||
RK-017-01 | PHOENIX PEPTIDE | 125 tubes | EUR 980.64 |
Amylin (1-13) (Human) - EIA Kit |
|||
EK-017-06 | PHOENIX PEPTIDE | 96 wells | EUR 603.72 |
Amylin (1-13) (Human) - RIA Kit |
|||
RK-017-06 | PHOENIX PEPTIDE | 125 tubes | EUR 980.64 |
Amylin (Rat, Mouse) - Antibody |
|||
H-017-11 | PHOENIX PEPTIDE | 50 μl | EUR 238.68 |
Amylin (21-27) / IAPP(21-27) (Human) |
|||
017-20 | PHOENIX PEPTIDE | 500 μg | EUR 206.28 |
Amylin (28-33) / IAPP(28-33) (Human) |
|||
017-22 | PHOENIX PEPTIDE | 500 μg | EUR 206.28 |
Amylin / IAPP (Human) - Antibody |
|||
H-017-03 | PHOENIX PEPTIDE | 50 μl | EUR 238.68 |
Amylin amide (Human) - Antibody |
|||
H-017-04 | PHOENIX PEPTIDE | 100 μl | EUR 469.8 |
Amylin (25-37) amide (Human) - RIA Kit |
|||
RK-017-10 | PHOENIX PEPTIDE | 125 tubes | EUR 980.64 |
Amylin (Rat, Mouse) - EIA Kit |
|||
EK-017-11 | PHOENIX PEPTIDE | 96 wells | EUR 603.72 |
Amylin (Rat, Mouse) - RIA Kit |
|||
RK-017-11 | PHOENIX PEPTIDE | 125 tubes | EUR 980.64 |
Amylin / IAPP (Human) - EIA Kit |
|||
EK-017-03 | PHOENIX PEPTIDE | 96 wells | EUR 603.72 |
Amylin amide (Human) - RIA Kit |
|||
RK-017-04 | PHOENIX PEPTIDE | 125 tubes | EUR 980.64 |
Amylin (Rat, Mouse) - FAM Labeled |
|||
FG-017-11A | PHOENIX PEPTIDE | 1 nmol | EUR 267.84 |
Amylin / IAPP (Human) - FAM Labeled |
|||
FG-017-03A | PHOENIX PEPTIDE | 1 nmol | EUR 267.84 |
Amylin (Feline) - I-125 Labeled |
|||
T-017-01 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Amylin (1-13) (Human) - Fluorescent EIA Kit |
|||
FEK-017-06 | PHOENIX PEPTIDE | 96 wells | EUR 660.96 |
Amylin (25-37) amide (Human) - I-125 Labeled |
|||
T-017-10 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Amylin (1-13) (Human) - Purified IgG Antibody |
|||
G-017-06 | PHOENIX PEPTIDE | 100 μg | EUR 336.96 |
Amylin (Feline) - Purified IgG Antibody |
|||
G-017-01 | PHOENIX PEPTIDE | 400 μg | EUR 506.52 |
[Tyr0]-Amylin (1-13) (Human) - I-125 Labeled |
|||
T-017-07 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Rabbit anti Amylin Peptide Polyclonal Antibody |
|||
TA354264 | Origene Technologies GmbH | 100 µg | Ask for price |
Rabbit anti Amylin Peptide Polyclonal Antibody |
|||
MBS460173-01mg | MyBiosource | 0.1mg | EUR 320 |
Rabbit anti Amylin Peptide Polyclonal Antibody |
|||
MBS460173-5x01mg | MyBiosource | 5x0.1mg | EUR 1390 |
Amylin (Rat, Mouse) - I-125 Labeled |
|||
T-017-11 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Amylin / IAPP (Human) - I-125 Labeled |
|||
T-017-03 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Amylin (Rat, Mouse) - Fluorescent EIA Kit |
|||
FEK-017-11 | PHOENIX PEPTIDE | 96 wells | EUR 660.96 |
Impact of methotrexate therapy on the expression of epidermal-fatty acid-binding protein (E-FABP) and apolipoproteins in sufferers with psoriasis
Introduction: Epidermal-fatty acid-binding protein (E-FABP) is a marker of transiently amplifying cells that are fashioned from stem cells in dermis. Their position is an uptake of fatty acids and metabolism. Psoriatic keratinocytes overexpress E-FABPs, which ends up in acanthosis and will clarify the lipid’s disturbances in psoriasis.
Purpose: Evaluation of FABP and apolipoprotein expression in sufferers handled with methotrexate (MTX).
Materials and strategies: FABP expression within the lesional and perilesional psoriatic pores and skin from 11 male sufferers in comparison with 5 wholesome pores and skin samples had been evaluated by immunohistochemistry. FABP, apolipoprotein A1 (ApoA1) and B (ApoB) serum ranges had been assessed by ELISA. These parameters had been evaluated earlier than and after therapy with subcutaneous MTX (15 mg/wk for 12 weeks).
Outcomes: Expression of E-FABP was decrease within the management group than within the lesional and perilesional psoriatic pores and skin, earlier than and after therapy. After therapy the expression decreased within the lesional and perilesional pores and skin. Serum E-FABP was greater within the management group (482.855 ±240.550 pg/ml) in comparison with sufferers, however not statistically considerably.
After MTX therapy, a statistically important discount was noticed in psoriatic sufferers. ApoA1 ranges didn’t differ within the management and sufferers teams, each earlier than and after therapy. In distinction, ApoB ranges didn’t differ statistically between the management group (1447.126 ±311.11 ng/ml) and sufferers earlier than therapy, whereas they had been the bottom after therapy (1081.67 ±117.83 ng/ml vs. 808.306 ±103.72 ng/ml; p < 0.01).
Conclusions: Our examine confirms the useful impact of MTX, not solely as an anti-proliferative impact, but in addition lowering the cardiovascular danger by lowering atherogenic ApoB.
Key phrases: apolipoprotein; fatty acid-binding protein; methotrexate; psoriasis.
ARC/Nucleolar protein 3 Antibody |
|||
MBS856368-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
ARC/Nucleolar protein 3 Antibody |
|||
MBS856368-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
ARC/Nucleolar protein 3 Antibody |
|||
MBS856368-02mL | MyBiosource | 0.2mL | EUR 345 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
20-abx114218 | Abbexa |
|
|
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx038406-100ug | Abbexa | 100 ug | EUR 469.2 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
20-abx004831 | Abbexa |
|
|
Nucleolar Protein 3 (NOL3) Antibody |
|||
20-abx210877 | Abbexa |
|
|
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx235784-100ug | Abbexa | 100 ug | EUR 577.2 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx331497-100ul | Abbexa | 100 ul | EUR 510 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
20-abx318527 | Abbexa |
|
|
Nucleolar Protein 3 (NOL3) Antibody |
|||
20-abx320690 | Abbexa |
|
|
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx114218-100l | Abbexa | 100 µl | EUR 612.5 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx210877-100l | Abbexa | 100 µl | EUR 350 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx210877-50l | Abbexa | 50 µl | EUR 250 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx037829-96tests | Abbexa | 96 tests | EUR 337.5 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx038406-100g | Abbexa | 100 µg | EUR 337.5 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx235784-100g | Abbexa | 100 µg | EUR 350 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx324845-100g | Abbexa | 100 µg | EUR 250 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx324845-50g | Abbexa | 50 µg | EUR 187.5 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx320690-100l | Abbexa | 100 µl | EUR 350 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx320690-50l | Abbexa | 50 µl | EUR 250 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx318527-100l | Abbexa | 100 µl | EUR 250 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx318527-50l | Abbexa | 50 µl | EUR 162.5 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx013023-100g | Abbexa | 100 µg | EUR 237.5 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx013023-10g | Abbexa | 10 µg | EUR 43.75 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx013023-200g | Abbexa | 200 µg | EUR 312.5 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx004831-100l | Abbexa | 100 µl | EUR 400 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx004831-20l | Abbexa | 20 µl | EUR 175 |
Nucleolar Protein 3 (NOL3) Antibody |
|||
abx004831-50l | Abbexa | 50 µl | EUR 275 |
Nucleolar Protein 3 (NOL3) Antibody (HRP) |
|||
20-abx304651 | Abbexa |
|
|
Nucleolar Protein 3 (NOL3) Antibody (HRP) |
|||
abx304651-100g | Abbexa | 100 µg | EUR 362.5 |
Nucleolar Protein 3 (NOL3) Antibody (HRP) |
|||
abx304651-20g | Abbexa | 20 µg | EUR 162.5 |
Nucleolar Protein 3 (NOL3) Antibody (HRP) |
|||
abx304651-50g | Abbexa | 50 µg | EUR 250 |
Nucleolar Protein 3 (NOL3) Antibody (FITC) |
|||
20-abx304652 | Abbexa |
|
|
Nucleolar Protein 3 (NOL3) Antibody (FITC) |
|||
abx304652-100g | Abbexa | 100 µg | EUR 362.5 |
Nucleolar Protein 3 (NOL3) Antibody (FITC) |
|||
abx304652-20g | Abbexa | 20 µg | EUR 162.5 |
Nucleolar Protein 3 (NOL3) Antibody (FITC) |
|||
abx304652-50g | Abbexa | 50 µg | EUR 250 |
Nucleolar Protein 3 (NOL3) Antibody (Biotin) |
|||
20-abx304653 | Abbexa |
|
|
Nucleolar Protein 3 (NOL3) Antibody (Biotin) |
|||
abx304653-100g | Abbexa | 100 µg | EUR 362.5 |
Nucleolar Protein 3 (NOL3) Antibody (Biotin) |
|||
abx304653-20g | Abbexa | 20 µg | EUR 162.5 |
Nucleolar Protein 3 (NOL3) Antibody (Biotin) |
|||
abx304653-50g | Abbexa | 50 µg | EUR 250 |
Nucleolar protein 58 Antibody (HRP) |
|||
20-abx108572 | Abbexa |
|
|
Nucleolar protein 58 Antibody (FITC) |
|||
20-abx107151 | Abbexa |
|
|
Nucleolar protein 58 Antibody (Biotin) |
|||
20-abx105733 | Abbexa |
|
|
Nucleolar Protein 9 (NOL9) Antibody |
|||
abx122121-100ug | Abbexa | 100 ug | EUR 469.2 |
Nucleolar Protein 9 (NOL9) Antibody |
|||
20-abx124786 | Abbexa |
|
|
Nucleolar Protein 8 (NOL8) Antibody |
|||
20-abx141132 | Abbexa |
|
|
Nucleolar Protein 8 (NOL8) Antibody |
|||
20-abx114219 | Abbexa |
|
|
Nucleolar Protein 9 (NOL9) Antibody |
|||
abx034569-400ul | Abbexa | 400 ul | EUR 627.6 |
Nucleolar Protein 9 (NOL9) Antibody |
|||
abx034569-80l | Abbexa | 80 µl | EUR 343.2 |
Nucleolar Protein 4 (NOL4) Antibody |
|||
abx029414-400ul | Abbexa | 400 ul | EUR 627.6 |
Nucleolar Protein 4 (NOL4) Antibody |
|||
abx029414-80l | Abbexa | 80 µl | EUR 343.2 |
Nucleolar Protein 9 (NOL9) Antibody |
|||
20-abx211330 | Abbexa |
|
|
Nucleolar Protein 4 (NOL4) Antibody |
|||
abx235785-100ug | Abbexa | 100 ug | EUR 577.2 |
Nucleolar Protein 6 (NOL6) Antibody |
|||
abx235786-100ug | Abbexa | 100 ug | EUR 577.2 |
Nucleolar Protein 6 (NOL6) Antibody |
|||
abx235787-100ug | Abbexa | 100 ug | EUR 610.8 |
Nucleolar Protein 8 (NOL8) Antibody |
|||
abx235788-100ug | Abbexa | 100 ug | EUR 610.8 |
Nucleolar Protein 9 (NOL9) Antibody |
|||
abx235789-100ug | Abbexa | 100 ug | EUR 661.2 |
Nucleolar Protein 4 (NOL4) Antibody |
|||
20-abx217203 | Abbexa |
|
|
Nucleolar Protein 8 (NOL8) Antibody |
|||
20-abx217204 | Abbexa |
|
|
Nucleolar Protein 7 (NOL7) Antibody |
|||
20-abx217284 | Abbexa |
|
|
Nucleolar Protein 8 (NOL8) Antibody |
|||
20-abx324504 | Abbexa |
|
|
Nucleolar Protein 6 (NOL6) Antibody |
|||
20-abx301690 | Abbexa |
|
|
NOP2 Antibody / Nucleolar protein 2 |
|||
F53988-0.05ML | NSJ Bioreagents | 0.05 ml | EUR 140.25 |
Description: Nucleolar protein 2 is an S-adenosyl-L-methionine-dependent methyltransferase that specifically methylates the C(5) position of cytosine 4447 in 28S rRNA (Probable). May play a role in the regulation of the cell cycle and the increased nucleolar activity that is associated with the cell proliferation. |
NOP2 Antibody / Nucleolar protein 2 |
|||
F53988-0.2ML | NSJ Bioreagents | 0.2 ml | EUR 322.15 |
Description: Nucleolar protein 2 is an S-adenosyl-L-methionine-dependent methyltransferase that specifically methylates the C(5) position of cytosine 4447 in 28S rRNA (Probable). May play a role in the regulation of the cell cycle and the increased nucleolar activity that is associated with the cell proliferation. |
Nucleolar Protein 8 (NOL8) Antibody |
|||
abx114219-100l | Abbexa | 100 µl | EUR 612.5 |
Nucleolar Protein 9 (NOL9) Antibody |
|||
abx211330-100l | Abbexa | 100 µl | EUR 350 |
Nucleolar Protein 9 (NOL9) Antibody |
|||
abx211330-50l | Abbexa | 50 µl | EUR 250 |
Nucleolar Protein 9 (NOL9) Antibody |
|||
abx122121-100l | Abbexa | 100 µl | Ask for price |
Nucleolar Protein 9 (NOL9) Antibody |
|||
abx122121-20l | Abbexa | 20 µl | EUR 337.5 |
Nucleolar Protein 9 (NOL9) Antibody |
|||
abx122121-50l | Abbexa | 50 µl | Ask for price |
Nucleolar Protein 6 (NOL6) Antibody |
|||
abx301690-100g | Abbexa | 100 µg | EUR 362.5 |
Nucleolar Protein 6 (NOL6) Antibody |
|||
abx301690-20g | Abbexa | 20 µg | EUR 162.5 |
Nucleolar Protein 6 (NOL6) Antibody |
|||
abx301690-50g | Abbexa | 50 µg | EUR 250 |
Nucleolar Protein 9 (NOL9) Antibody |
|||
abx034569-100g | Abbexa | 100 µg | EUR 281.25 |
Nucleolar Protein 4 (NOL4) Antibody |
|||
abx029414-400l | Abbexa | 400 µl | EUR 518.75 |
Nucleolar Protein 4 (NOL4) Antibody |
|||
abx235785-100g | Abbexa | 100 µg | EUR 350 |
Nucleolar Protein 6 (NOL6) Antibody |
|||
abx235786-100g | Abbexa | 100 µg | EUR 350 |
Nucleolar Protein 6 (NOL6) Antibody |
|||
abx235787-100g | Abbexa | 100 µg | EUR 350 |
Nucleolar Protein 8 (NOL8) Antibody |
|||
abx235788-100g | Abbexa | 100 µg | EUR 350 |
Nucleolar Protein 9 (NOL9) Antibody |
|||
abx235789-100g | Abbexa | 100 µg | EUR 350 |
Nucleolar Protein 7 (NOL7) Antibody |
|||
abx217284-100tests | Abbexa | 100 tests | EUR 387.5 |
Nucleolar Protein 7 (NOL7) Antibody |
|||
abx217284-200tests | Abbexa | 200 tests | Ask for price |
Nucleolar Protein 7 (NOL7) Antibody |
|||
abx217284-20tests | Abbexa | 20 tests | EUR 300 |